Atyr Pharma INC

aTyr Pharma and Kyorin Pharmaceutical have mutually agreed to terminate their collaboration and license agreement, with aTyr regaining exclusive global rights to efzofitimod.

aTyr Pharma has secured an additional 180 days, until November 30, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.

aTyr Pharma presented an investor presentation detailing the advancement of its lead product candidate, efzofitimod, for pulmonary sarcoidosis and other interstitial lung diseases, highlighting trial insights and future development plans.

aTyr Pharma announced Q1 2026 results, detailing progress on efzofitimod development for pulmonary sarcoidosis and SSc-ILD, with a cash position of $68.3 million.

aTyr Pharma announces updated development plan for efzofitimod in pulmonary sarcoidosis following FDA Type C meeting, focusing on a new Phase 3 study with FVC as the primary endpoint.

aTyr Pharma announced its full year 2025 financial results and a corporate update, including the Phase 3 EFZO-FIT study failing to meet its primary endpoint for pulmonary sarcoidosis.

aTyr Pharma reported a net loss of $25.7 million for Q3 2025 and announced its lead therapeutic candidate, efzofitimod, failed to meet its primary endpoint in a pivotal Phase 3 pulmonary sarcoidosis study.

aTyr Pharma reports progress in its clinical trials for efzofitimod, with Phase 3 data expected in September 2025, but notes manufacturing deviations and continued net losses.

aTyr Pharma reports its Q1 2025 financial results, highlighting ongoing clinical trials for efzofitimod and providing an update on its financial condition.

aTyr Pharma's Q3 2024 report details financial results and progress in clinical trials, including the EFZO-FIT study for pulmonary sarcoidosis and the EFZO-CONNECT study for SSc-ILD.

aTyr Pharma's Q2 2024 report shows increased R&D spending, completion of enrollment for the EFZO-FIT study, and a net loss of $16.3 million.

aTyr Pharma's first quarter 2024 results show a net loss of $15.5 million, with ongoing clinical trial expenses and preparation for a potential biologics license application.

aTyr Pharma announced that its lead candidate, efzofitimod, failed to meet its primary endpoint in the Phase 3 EFZO-FIT study for pulmonary sarcoidosis, though secondary endpoints showed clinical improvements.

aTyr Pharma's 10-K filing summarizes the company's financial results for 2024 and provides an update on the clinical development of its lead drug candidate, efzofitimod, for interstitial lung diseases.

aTyr Pharma's 10-K filing outlines the structure of its common stock, preferred stock authorization, and various provisions designed to protect the company from hostile takeovers, while also detailing its clinical programs and regulatory landscape.

Director Paul Schimmel purchased 100,000 shares of aTyr Pharma, Inc. common stock at a weighted average price of $0.4963.

ATYR Pharma reports that Director Timothy Coughlin acquired 50,000 stock options with an exercise price of $0.95, vesting in full on May 11, 2027, or the 2027 Annual Meeting.

Eric Benevich, a Director at ATYR Pharma Inc., has acquired 50,000 stock options, signaling a potential long-term commitment to the company.

Jane A. Gross, a Director at ATYR Pharma Inc., acquired 50,000 stock options with an exercise price of $0.95.

Svetlana Lucas, a Director at ATYR Pharma Inc., acquired 50,000 stock options with an exercise price of $0.95.

ATYR Pharma director Sara Zaknoen acquired 50,000 stock options with an exercise price of $0.95, vesting in full on May 11, 2027, or the 2027 Annual Meeting.

aTyr Pharma sets date for its annual stockholder meeting and outlines key proposals for vote, including director elections and executive compensation.

aTyr Pharma's upcoming annual meeting on May 1, 2025, will address key corporate governance matters, including the election of directors, ratification of the auditor, executive compensation, and an amendment to the stock option plan.

aTyr Pharma will hold its annual meeting of stockholders on May 22, 2024, to vote on director elections, auditor ratification, executive compensation, and an amendment to the stock option plan.

aTyr Pharma announces its 2024 Annual Meeting of Stockholders to be held on May 22, 2024, featuring proposals including director elections, auditor ratification, executive compensation, and stock plan amendments.

Federated Hermes, Inc. and associated entities have filed an amended Schedule 13G, reporting beneficial ownership of 8,509,678 shares, representing 8.68% of aTyr Pharma Inc.'s common stock.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting a 6.1% beneficial ownership stake in aTyr Pharma Inc.

Federated Hermes, Inc. and its affiliated entities reported a beneficial ownership of 10.76% in aTYR PHARMA INC common stock as of September 30, 2025.

The Vanguard Group has reported a passive beneficial ownership of 5.23% in aTyr Pharma Inc., holding 4,655,048 shares of common stock.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 6.5% in aTYR Pharma Inc.'s common stock as of June 30, 2025.

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have disclosed a combined passive beneficial ownership of 3.2% in aTyr Pharma Inc., totaling 2,845,354 shares as of March 31, 2025.